The primary objective of the study is to assess the efficacy, safety, and tolerability of ABBV-154 in comparison with placebo in subjects with moderately to severely active CD who had inadequate response to or were intolerant of prior biologics.

Researchers are studying the long-term safety and tolerability of cendakimab for patients with eosinophilic esophagitis ("EoE"). The researchers hope to provide evidence to prove that cendakimab is a safe and effective medication for long-term EoE treatment.

This is an anonymous international research survey of primary care physicians (general practitioners), conducted to enhance understanding of diagnostic and treatment practices for irritable bowel syndrome (IBS) among such physicians in the U.S. and Europe, and to assess their knowledge and use of the Rome IV diagnostic criteria, which are the current recommended formal standard for diagnosis of the disorder.

The purpose of this program is to provide compassionate use of APT-1011 for adult and adolescent patients with eosinophilic esophagitis (EoE) who are unable or ineligible to enroll in an APT-1011 clinical study or have failed available treatment options

The purpose of this study is to learn more about how well the COVID-19 vaccine works for patients with IBD. This includes people with Crohn's disease and ulcerative colitis. We want to learn more about side effects and whether the vaccine impacts IBD activity. This study does not provide the COVID-19 vaccine and is only for people who have already received at least 1 vaccine.

Compare the efficacy and safety of risankizumab versus ustekinumab for the treatment of adult subjects with moderate to severe CD who have failed anti-TNF therapy.

During the COVID-19 pandemic, evidence has been gradually emerging indicating that gastrointestinal (GI) and liver symptoms and problems may play an important role in the disease, and there is growing concern that these effects may linger for extended periods, even long after recovery from the viral infection. The purpose of this study is to evaluate gastrointestinal disorders and digestive tract symptoms in people who have had COVID-19 in the past, as well as the after-effects on wellbeing and life functioning that may still remain after the illness, and to gain understanding of what factors determine the degree and nature of any such after-effects.

The purpose of this research study is to identify environmental factors, dietary factors, genetic factors, and other molecular factors that contribute to the development of Barrett's esophagus and esophageal cancer in individuals. The study aims to determine if an investigational sampling technique, the JASSS Balloon, is a well-tolerated and effective means to sample the esophagus and detect identified genes linked to the development of Barrett's Esophagus and esophageal cancer in individuals. This study will also develop new tests for helping doctors diagnose and manage these diseases.

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is doing this study because they want to learn more about eosinophilic gastrointestinal disorders (EGIDs).

The Thought Impact Scale (TIS) is a recently developed questionnaire. It measures a broad human psychological characteristic that varies greatly between individuals, and represents the global extent to which people's conscious mind communicates with their non-conscious mental functions in everyday life. Scores on the TIS questionnaire have shown potentially useful associations with important aspects of life functioning domains in past research. The purpose of the present study is to evaluate some of these further in a large national U.S. general population sample by means of a nationwide Internet survey: That is, assess the predicted relationships of high scores on the TIS questionnaire to (A) increased tendency to engage in creative and artistic activities and attend art events, (B) increased probability of mental health diagnoses and chronic stress-related disorders, and (C) tendencies to have unusually strong negative and positive reactions to medications, food and caffeine.